<DOC>
	<DOC>NCT01046916</DOC>
	<brief_summary>This is a multicenter phase 2 open-label single-arm study that will evaluate the safety and efficacy of TAK-700 in patients with castration-resistant prostate cancer (CRPC) without radiographic evidence of metastases who have a rising prostate-specific antigen (PSA).</brief_summary>
	<brief_title>Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Each patient must meet all of the following inclusion criteria: Male patients 18 years or older Eastern Cooperative Oncology Group performance status 02 Male patients who Practice effective barrier contraception during study and for 4 months after the last dose of study drug, OR Abstain from heterosexual intercourse. Voluntary written consent Histologically or cytologically confirmed diagnosis of prostate adenocarcinoma without radiographic evidence of metastasis but with a rising PSA during or following the patient's most recent antineoplastic therapy despite castrate concentrations of testosterone Baseline PSA must be greater than or equal to 2 ng/mL and PSA doubling time must be less than or equal to 8 months OR baseline PSA must be greater than or equal to 8 ng/mL if PSA doubling time is greater than 8 months Has undergone orchiectomy or will continue receiving GnRH analogue therapy Meet screening laboratory values as specified in protocol Patients meeting any of the following exclusion criteria are not to be enrolled in the study: Known hypersensitivity to TAK700 or related compounds Received any of the following within 30 days prior to the first dose of TAK700: any investigational compound; prior herbal product known to decrease PSA; radiation therapy for prostate cancer; OR chronic therapy with corticosteroids Received prior therapy with aminoglutethimide or ketoconazole Received antiandrogen therapy within 4 weeks for flutamide and 6 weeks for all others prior to first dose of study drug Received prior chemotherapy for prostate cancer Current bladder neck outlet obstruction caused by prostate cancer, current spinal cord compression, or current bilateral hydronephrosis Symptoms that investigator deems related to prostate cancer Diagnosis or treatment of another malignancy within 2 years preceding first dose of study drug except nonmelanoma skin cancer or in situ malignancy completely resected History of adrenal insufficiency Uncontrolled cardiovascular condition Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C Unwilling or unable to comply with protocol Major surgery or serious infection within 14 days of first dose of TAK700 Lifethreatening illness unrelated to cancer Uncontrolled nausea, vomiting or diarrhea Known gastrointestinal disease or procedure that could interfere with oral absorption or tolerance of TAK700</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>